Hence, in cardiovascular diseases characterized by reduced bioavailability of endothelium-derived NO, ET-1 and ETA-effects are upregulated[4] and can be tempered by counterbalancing effects of SMN[29], [30], [31]. Here, EDN1 is linked to cardiovascular disorder.